MA
RVNC

MYDA Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

MYDA Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-24,900
Closed -$890K – 189
2017
Q4 		$890K Buy
+24,900
New +$715K 0.39% 70

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

MYDA Advisors's RVNC Position: Q1 2018 in Review

MYDA Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2018, closing a stake of 8,000 shares — an estimated $286K sold.

MYDA Advisors first reported a position in RVNC in Q4 2017 and held it in 1 quarter. The position peaked at $286K in Q4 2017. 120 funds tracked by Wall St. Rank hold RVNC as of Q1 2018.

  • MYDA Advisors reported no remaining Revance Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • MYDA Advisors sold 8,000 Revance Therapeutics, Inc. shares in Q1 2018, an estimated $286K.
  • MYDA Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • MYDA Advisors's Revance Therapeutics, Inc. position peaked at $286K in Q4 2017.
  • 120 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2018.

Based on MYDA Advisors's 13F filing for Q1 2018, filed 10 May 2018.